Boston Scientific Corporation $BSX Shares Purchased by Banque Transatlantique SA

by · The Markets Daily

Banque Transatlantique SA boosted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 54.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 927,478 shares of the medical equipment provider’s stock after buying an additional 328,434 shares during the period. Boston Scientific makes up about 2.8% of Banque Transatlantique SA’s investment portfolio, making the stock its 11th largest position. Banque Transatlantique SA owned 0.06% of Boston Scientific worth $99,799,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Riverwater Partners LLC lifted its holdings in shares of Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management increased its holdings in Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 99 shares in the last quarter. IVC Wealth Advisors LLC raised its position in Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares during the period. Rise Advisors LLC lifted its stake in shares of Boston Scientific by 13.9% during the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 103 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its position in shares of Boston Scientific by 3.9% in the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after buying an additional 103 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX opened at $92.58 on Friday. The company has a market capitalization of $137.24 billion, a P/E ratio of 49.51, a PEG ratio of 1.85 and a beta of 0.67. The company has a 50-day moving average of $98.85 and a 200-day moving average of $101.64. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on BSX shares. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the company from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partners lifted their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Wells Fargo & Company raised their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $124.43.

View Our Latest Research Report on BSX

About Boston Scientific

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).